UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 548

Sortiert nach

Municipal solid waste management in China: a comparative analysis

Journal of material cycles and waste management, 2017-07, Vol.19 (3), p.1127-1135

2017

Volltextzugriff (PDF)

Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery

Nature protocols, 2023-08, Vol.18 (8), p.2509-2557

2023

Volltextzugriff (PDF)

Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Bone marrow transplantation (Basingstoke), 2023-09

2023

Volltextzugriff (PDF)

Ionic Liquid Coating‐Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV

Advanced science, 2024-06, Vol.11 (23), p.e2305484-n/a

2024

Volltextzugriff (PDF)

Two decades of echinococcosis/hydatidosis research: Bibliometric analysis based on the web of science core collection databases (2000–2019)

Food and waterborne parasitology, 2021-12, Vol.25, p.e00137-e00137, Article e00137

2021

Volltextzugriff (PDF)

Lipid nanoparticle-mediated drug delivery to the brain

Advanced drug delivery reviews, 2023-06, Vol.197, p.114861-114861, Article 114861

2023

Volltextzugriff (PDF)

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Dispersive liquid–liquid microextraction based on the solidification of floating organic drop followed by ICP-MS for the simultaneous determination of heavy metals in wastewaters

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015-04, Vol.140, p.156-161

2015

Volltextzugriff (PDF)

P1717: HEALTH‐RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH‐RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1598-1599

2022

Volltextzugriff (PDF)

LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

HemaSphere, 2022-06, Vol.6 (Suppl), p.994-995

2022

Volltextzugriff (PDF)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS‐5)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1989-1990

2022

Volltextzugriff (PDF)

Shot-Noise Limited Single-Molecule FRET Histograms: Comparison between Theory and Experiments

The journal of physical chemistry. B, 2006-11, Vol.110 (44), p.22103-22124

2006

Volltextzugriff (PDF)

PB2119: LONG‐TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE‐TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1990-1991

2022

Volltextzugriff (PDF)

Improved nanoformulation and bio-functionalization of linear-dendritic block copolymers with biocompatible ionic liquids

Nanoscale, 2022-04, Vol.14 (16), p.621-636

2022

Volltextzugriff (PDF)

Dispersive liquid-liquid microextraction method based on solidification of floating organic droplet for the determination of thiamphenicol and florfenicol in environmental water samples

Ecotoxicology and environmental safety, 2015-05, Vol.115, p.229-233

2015

Volltextzugriff (PDF)

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.93-95

2019

Volltextzugriff (PDF)

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)

Hematological oncology, 2019-06, Vol.37 (S2), p.95-97

2019

Volltextzugriff (PDF)

Imidazolium-based zwitterionic liquid-modified PEG-PLGA nanoparticles as a potential intravenous drug delivery carrier

Nanoscale, 2024-03, Vol.16 (11), p.5584-56

2024

Volltextzugriff (PDF)

P1344: METHODOLOGY OF AN INTERNATIONAL MULTI‐CENTER RETROSPECTIVE REVIEW OF TRANSPLANT‐ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA‐TMA) BY THE TA‐TMA WORKING GROUP

HemaSphere, 2022-06, Vol.6 (Suppl), p.1229-1230

2022

Volltextzugriff (PDF)

INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.270-271

2017

Volltextzugriff (PDF)

Protein-avoidant ionic liquid (PAIL)-coated nanoparticles to increase bloodstream circulation and drive biodistribution

Science advances, 2020-11, Vol.6 (48)

2020

Volltextzugriff (PDF)

FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL

Hematological oncology, 2017-06, Vol.35 (S2), p.49-51

2017

Volltextzugriff (PDF)

1 – 25 von 548

Suche als RSS-Feed

Aktive Filter

ThemaTransplantation

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(430)
Mit Volltextzugriff
(512)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(229)
Life Sciences & Biomedicine
(186)
Humans
(149)
Female
(97)
Male
(84)
Adult
(61)
Middle Aged
(53)
Infant
(43)
Hematology
(42)
Aged
(41)
Oncology
(41)
Biological And Medical Sciences
(39)
Bangladesh
(38)
Hematology, Oncology And Palliative Medicine
(36)
Medical Sciences
(33)
Child Development
(31)
Child, Preschool
(31)
Young Adult
(31)
Physical Sciences
(30)
Technology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Municipal solid waste management in China: a comparative analysis

Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery

Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Ionic Liquid Coating‐Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV

Two decades of echinococcosis/hydatidosis research: Bibliometric analysis based on the web of science core collection databases (2000–2019)

Lipid nanoparticle-mediated drug delivery to the brain

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

Dispersive liquid–liquid microextraction based on the solidification of floating organic drop followed by ICP-MS for the simultaneous determination of heavy metals in wastewaters

P1717: HEALTH‐RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH‐RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)

LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS‐5)

Shot-Noise Limited Single-Molecule FRET Histograms: Comparison between Theory and Experiments

PB2119: LONG‐TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE‐TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

Improved nanoformulation and bio-functionalization of linear-dendritic block copolymers with biocompatible ionic liquids

Dispersive liquid-liquid microextraction method based on solidification of floating organic droplet for the determination of thiamphenicol and florfenicol in environmental water samples

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)

Imidazolium-based zwitterionic liquid-modified PEG-PLGA nanoparticles as a potential intravenous drug delivery carrier

P1344: METHODOLOGY OF AN INTERNATIONAL MULTI‐CENTER RETROSPECTIVE REVIEW OF TRANSPLANT‐ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA‐TMA) BY THE TA‐TMA WORKING GROUP

INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA

Protein-avoidant ionic liquid (PAIL)-coated nanoparticles to increase bloodstream circulation and drive biodistribution

FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Aktive Filter

Suchergebnisse filtern